Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):  A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption

• Published in: Journal of medicinal chemistry 1998-03, Vol.41 (6), p.973-980
• Main Authors: Rosenblum, Stuart B, Huynh, Tram, Afonso, Adriano, Davis, Harry R, Yumibe, Nathan, Clader, John W, Burnett, Duane A
• Format: Article
• Language: English
• Subjects: Animals; Anticholesteremic Agents - chemistry; Anticholesteremic Agents - metabolism; Anticholesteremic Agents - pharmacology; Azetidines - chemistry; Azetidines - metabolism; Azetidines - pharmacology; Biological and medical sciences; Cholesterol - administration & dosage; Cholesterol - blood; Cricetinae; Drug Design; Ezetimibe; General and cellular metabolism. Vitamins; Liver - drug effects; Liver - metabolism; Medical sciences; Pharmacology. Drug treatments; Structure-Activity Relationship
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm970701f

(3R)-(3-Phenylpropyl)-1,(4S)-bis(4-methoxyphenyl)-2-azetidinone (2, SCH 48461), a novel inhibitor of intestinal cholesterol absorption, has recently been described by Burnett et al. and has been demonstrated to lower total plasma cholesterol in man. The potential sites of metabolism of 2 were considered, and the most probable metabolites were prepared. The oral cholesterol-lowering efficacy of the putative metabolites was evaluated in a 7-day cholesterol-fed hamster model for the reduction of serum total cholesterol and liver cholesteryl esters versus control. On the basis of our analysis of the putative metabolite structure−activity relationship (SAR), SCH 58235 (1, 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone) was designed to exploit activity enhancing oxidation and to block sites of potential detrimental metabolic oxidation. Additionally, a series of congeners of 2 were prepared incorporating strategically placed hydroxyl groups and fluorine atoms to further probe the SAR of 2-azetidinone cholesterol absorption inhibitors. Through the SAR analysis of a series of putative metabolites of 2, compound 1 was targeted and found to exhibit remarkable efficacy with an ED50 of 0.04 mg/kg/day for the reduction of liver cholesteryl esters in a 7-day cholesterol-fed hamster model.